Who is BT for?

The Alair™ Bronchial Thermoplasty System is indicated for the treatment of severe persistent asthma in patients 18 years and older whose asthma is not well controlled with inhaled corticosteroids and long-acting beta-agonists (ICS and LABA), such as Advair™, Symbicort™, Breo™, or Dulera™.

Your asthma may not be well controlled if you are:

  • Still having severe asthma attacks
  • Adjusting your lifestyle to avoid asthma triggers
  • Absent from work, school, or daily activities because of your severe asthma

BT is not right for patients who:

  • Are under 18 years old
  • Have a pacemaker, internal defibrillator, or other implantable electronic device
  • Have known sensitivity to medications required to perform bronchoscopy, including lidocaine, atropine and benzodiazepines
  • Have previously been treated with BT

What to expect from BT

BT is not a cure for your severe asthma but may help to improve your asthma-related quality of life. It's different for each patient but clinical trials showed that many patients experienced reductions in severe asthma attacks, ER visits, and hospitalizations for respiratory symptoms, and fewer days lost from work, school, and other daily activities due to severe asthma.

Have Questions About Bronchial Thermoplasty?

Call BT CareConnectTM to speak with a trained professional who can help you.

Call (888) 272-8440 

Monday-Friday 9:00 AM - 8:00 PM Eastern
Find a BT doctor

Find a BT doctor

Locate a BT-certified pulmonologist in your area and learn more about insurance coverage.
Brief Statement of Relevant Indications for Use, Contraindications, Warnings, and Adverse Events:The Alair™ Bronchial ThermoplastySystem is indicated for the treatment of severe persistent asthma in patients 18 years and older whose asthma is not well controlled with inhaled corticosteroids and long-acting beta-agonists. The Alair System is not for use in patients with an active implantable electronic device or known sensitivity to medications used in bronchoscopy. Previously treated airways of the lung should not be retreated with the Alair System. Patients should be stable and suitable to undergo bronchoscopy. The most common side effect of BT is an expected transient increase in the frequency and worsening of respiratory-related symptoms. ENDO-551804-AA
As with any procedure, there are risks, and individual results may vary. The most common adverse event of BT is a temporary worsening of respiratory-related symptoms. These events typically occur within one day of the BT procedure and usually resolve within a week with standard care. There is a small risk (3.4% per procedure) that symptoms may require hospitalization.1

References

  1. Castro M, et al, for the AIR2 Trial Study Group. Am J Respir Crit Care Med. 2010;181:116-124.
Top